Edwards Lifesciences (NYSE:EW) Updates Q2 Earnings Guidance

Edwards Lifesciences (NYSE:EW) issued an update on its second quarter earnings guidance on Thursday morning. The company provided earnings per share guidance of $0.67-0.71 for the period, compared to the consensus earnings per share estimate of $0.70. The company issued revenue guidance of $1.62-1.70 billion, compared to the consensus revenue estimate of $1.65 billion. Edwards Lifesciences also updated its FY 2024 guidance to 2.700-2.800 EPS.

Edwards Lifesciences Price Performance

EW stock traded down $1.58 during trading on Friday, hitting $86.43. The company had a trading volume of 4,979,943 shares, compared to its average volume of 2,883,164. The company has a fifty day moving average price of $90.28 and a two-hundred day moving average price of $78.89. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The company has a market cap of $52.02 billion, a P/E ratio of 37.25, a P/E/G ratio of 4.29 and a beta of 1.05. Edwards Lifesciences has a fifty-two week low of $60.57 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a return on equity of 23.34% and a net margin of 23.01%. Equities research analysts expect that Edwards Lifesciences will post 2.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on EW. Bank of America upgraded Edwards Lifesciences from a neutral rating to a buy rating in a report on Thursday, March 7th. Piper Sandler increased their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the stock a neutral rating in a report on Friday. OTR Global upgraded Edwards Lifesciences from a mixed rating to a positive rating in a report on Tuesday, March 26th. StockNews.com downgraded Edwards Lifesciences from a buy rating to a hold rating in a report on Wednesday, March 20th. Finally, Mizuho increased their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a buy rating in a report on Thursday, April 11th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of Moderate Buy and a consensus price target of $93.33.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Edwards Lifesciences news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the transaction, the director now directly owns 4,486 shares of the company’s stock, valued at approximately $388,801.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 194,004 shares of company stock worth $17,166,254. Company insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.